Next Article in Journal
The L10P Polymorphism and Serum Levels of Transforming Growth Factor β1 in Human Breast Cancer
Previous Article in Journal
Functional Diversity of RNAi-Associated sRNAs in Fungi
Article Menu

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2013, 14(8), 15361-15375; doi:10.3390/ijms140815361

Addition of Aliskiren to Angiotensin Receptor Blocker Improves Ambulatory Blood Pressure Profile and Cardiorenal Function Better than Addition of Benazepril in Chronic Kidney Disease

Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan
*
Author to whom correspondence should be addressed.
Received: 13 May 2013 / Revised: 25 June 2013 / Accepted: 28 June 2013 / Published: 24 July 2013
View Full-Text   |   Download PDF [230 KB, uploaded 19 June 2014]

Abstract

An altered ambulatory blood pressure (BP) and heart rate (HR) profile is related to chronic kidney disease (CKD) and cardiorenal syndrome. In this study, we examined the effects of aliskiren, when added to angiotensin II type 1 receptor blockers, on ambulatory BP and cardiorenal function in CKD. Thirty-six hypertensive CKD patients were randomly assigned to the aliskiren add-on group (n = 18) or the benazepril add-on group (n = 18). Ambulatory BP and cardiorenal function parameters were measured at baseline and 24 weeks after treatment. Compared with the benazepril group, nighttime systolic BP variability in the aliskiren group was lower after treatment. Albuminuria was decreased in the aliskiren group, but not in the benazepril group. In addition, left ventricular mass index (LVMI) was significantly lower in the aliskiren group than in the benazepril group after treatment. In the aliskiren group, multivariate linear regression analysis showed an association between changes in albuminuria and changes in nighttime systolic BP. Furthermore, there were associations between changes in LVMI and changes in daytime HR variability, as well as between changes in LVMI and changes in plasma aldosterone concentration. These results suggest that aliskiren add-on therapy may be beneficial for suppression of renal deterioration and pathological cardiac remodeling through an improvement that is effected in ambulatory BP and HR profiles. View Full-Text
Keywords: albuminuria; ambulatory blood pressure; direct renin inhibitor; left ventricular hypertrophy; hypertension (kidney) albuminuria; ambulatory blood pressure; direct renin inhibitor; left ventricular hypertrophy; hypertension (kidney)
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Ohsawa, M.; Tamura, K.; Kanaoka, T.; Wakui, H.; Maeda, A.; Dejima, T.; Azushima, K.; Uneda, K.; Kobayashi, R.; Tsurumi-Ikeya, Y.; Toya, Y.; Fujikawa, T.; Umemura, S. Addition of Aliskiren to Angiotensin Receptor Blocker Improves Ambulatory Blood Pressure Profile and Cardiorenal Function Better than Addition of Benazepril in Chronic Kidney Disease. Int. J. Mol. Sci. 2013, 14, 15361-15375.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top